KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31

Korsana Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$31.41−0.97 (-3.00%)

Close on Oct 19, 2026

Market cap: $133.52M
P/E (TTM): –
Dividend yield: –

Korsana Biosciences, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31
Depreciation & Amortization	–	–	0	0.07	0.47	2.30	2.70	1.53	–
Stock-Based Compensation	0.44	0.63	1.07	6.25	9.61	15	20	12	–
Change in Accounts Receivable	-0.44	-0.56	0.10	0.00	-0.10	0	–	–	–
Change in Accounts Payable	0.12	-0.45	-1.77	1.14	0.68	-1.30	-0.33	0.98	–
Operating Cash Flow	-3.31	-4.33	-21	-41	-37	-72	-102	-98	–
Capital Expenditures	–	–	–	0	-0.01	-1.52	-6.89	-3.44	–
Sale of Property, Plant & Equipment	–	–	–	0	1.46	1.54	0.17	–	–
Divestitures	–	0	10	0	–	–	–	–	–
Investing Cash Flow	–	0	10	0	1.46	0.02	-6.72	-3.44	–
Stock Issued	1.38	0	5.00	0	–	–	–	–	–
Financing Cash Flow	3.32	0	5.02	0.03	31	28	212	101	–
Foreign Exchange Rate Adjustments	0	-0.01	0.01	0.00	0.00	-0.01	-0.02	–	–
Net Change in Cash	0.01	-4.34	-5.81	-41	-4.27	-44	103	125	0
Free Cash Flow	–	–	–	-41	-37	-74	-109	-101	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -359.2%
Net margin: -353.0%
Return on equity, FY2025: -39.3%

Financial strength

Current ratio: 0.82
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 75.5%

Valuation

P/E ratio: –
Price to sales: 70.28
Price to book: 26.25
Dividend yield: –